CIDP

CIDP

Chronic Inflamatory Demyelinating PolyneuropathyBy Daniel Schwartz
Michael Caine
Listen with Sir Michael Caine™ and 1,000+ voices
Length2h 47m

About this audiobook

CIDP: Chronic Inflammatory Demyelinating Polyneuropathy — A Complete Guide by Daniel Schwartz is a comprehensive, accessible 2026 guide to one of the most underdiagnosed autoimmune nerve diseases. CIDP occurs when the immune system mistakenly attacks the myelin sheath surrounding peripheral nerves, causing progressive weakness, numbness, pain, and loss of balance that unfolds over months to years — distinguishing it from the acute, self-limited Guillain-Barré Syndrome it closely resembles. Schwartz walks readers through the full arc of the disease. Written for patients, families, nursing and medical students, and curious non-specialists alike, the book pairs clear plain-language explanations with comparison tables, a full glossary, and practical appendices — symptom diaries, medication logs, and a guide to reading nerve conduction reports — empowering readers to understand their diagnosis and participate meaningfully in their own care.

Audiobook details

GenreHealth and Wellness
Length2 hrs 47 mins
Narrated byListen with 1,000+ voices
FormateBook with Audio
Publish dateApr 13, 2026
LanguageEnglish

Table of contents

1Introduction
59Clinical Evidence: The ADHERE Trial and Real-World Experience
2Foreword: A Note to Readers
607.5 Immunosuppressant Agents
3Chapter 1: What Is CIDP?
617.6 Rituximab — B-Cell Depletion
41.1 The Big Picture
627.7 Pain Management
51.2 Peripheral Nerves: What Are They?
637.7.1 The Role of Benzodiazepines in CIDP: Tremor, Muscle Spasms, and Anxiety
Show all chapters
61.3 The Word "Demyelinating" — What It Means
64Tremor in CIDP
71.4 Chronic vs. Acute: How CIDP Differs from GBS
65Muscle Spasms and Cramps
81.5 Why CIDP Is Often Underdiagnosed
66Anxiety in CIDP
9Chapter 2: A History of CIDP
677.9 Comprehensive Treatment Comparison
102.1 Early Observations of Peripheral Nerve Disease
687.10 Treatment Algorithm: Step-by-Step Overview
112.2 Guillain, Barré, and Strohl (1916)
69Chapter 8: Living with CIDP
122.3 The 1950s and 1960s: A Chronic Form Emerges
708.1 Rehabilitation: Rebuilding Strength and Function
132.4 Peter Dyck and the Formal Definition (1975)
718.2 Managing Fatigue
142.5 The 1980s–1990s: New Treatments and Confirmation
728.3 Psychological Impact and Mental Health
152.6 The 2000s–2010s: Subtypes and Biological Targets
738.4 Nutrition and General Wellness
162.7 The 2020s: Targeted Therapies and Personalized Medicine
748.5 Monitoring, Follow-Up, and Reassessing Treatment Need
17Chapter 3: Epidemiology — Who Gets CIDP?
758.6 Prognosis: What Can Patients Expect?
183.1 How Common Is CIDP?
76Chapter 9: Special Populations and Associated Conditions
193.2 Age and Sex Distribution
779.1 CIDP and Diabetes Mellitus
203.3 Geographic and Ethnic Distribution
789.2 CIDP in Children (Pediatric CIDP)
213.4 Risk Factors and Associated Conditions
799.3 CIDP and Monoclonal Gammopathy (MGUS and Related Disorders)
223.5 Economic and Social Burden
809.4 CIDP-Related Nodopathies: A Distinct Category
23Chapter 4: Pathology — What Happens Inside the Nerve?
819.5 CIDP in Pregnancy
244.1 The Immune Attack: An Overview
829.6 CIDP and COVID-19
254.2 The Blood-Nerve Barrier
83Chapter 10: Research and the Future of CIDP
264.3 The Node of Ranvier: Architecture and Vulnerability
8410.1 The Search for Reliable Biomarkers
274.4 Demyelination, Remyelination, and Onion Bulbs
8510.2 Precision Medicine: Matching Treatment to Biology
284.5 What the Nerve Biopsy Shows
8610.3 Reducing Treatment Burden and Achieving Remission
294.6 Key Antibody Targets: A New Era of Understanding
8710.4 Clinical Trials: How Patients Can Participate
304.7 Recognized Clinical Subtypes of CIDP
8810.5 International Collaboration and Patient Registries
31Chapter 5: Symptoms — What Does CIDP Feel Like?
89References and Further Reading
325.1 The Typical Presentation
90Foundational and Historical Works
335.2 Motor Symptoms — Weakness and Movement Problems
91Diagnostic Guidelines
345.3 Sensory Symptoms — Abnormal Feelings
92Key Treatment Trials
355.4 Balance and Gait Problems
93Emerging Therapies — 2024 to 2026
365.5 Less Common Symptoms
94Pathophysiology and Antibody Subtypes
375.6 Clinical Courses Over Time
95Reviews and Systematic Analyses
385.7 Impact on Daily Life and Quality of Life
96Patient Resources (Current as of April 2026)
39Chapter 6: Diagnosis — How Is CIDP Identified?
97Glossary of Key Terms
406.1 Why Diagnosis Is Challenging
98Appendix A: Patient Symptom and Treatment Diary: Treatment Log
416.2 Clinical History and Neurological Examination
99Appendix B: Understanding Your Nerve Conduction Study Report: Key Terms Explained
426.3 Nerve Conduction Studies (NCS) and Electromyography (EMG)
100Appendix C: Questions to Ask Your Neurologist
436.4 Cerebrospinal Fluid (CSF) Analysis
101At the Time of Diagnosis
446.5 MRI of the Spine and Peripheral Nerves
102At Follow-Up Appointments
456.6 Blood Tests
103About Daily Life
466.7 Nerve Biopsy
104Appendix D: CIDP Rating Scales Used in Research and Practice
476.8 Diagnostic Certainty Levels and the Treatment Trial: 6.8.1 How Many Nerves Must Be Abnormal? The 2021 NCS Demyelination Criteria
105MRC Sum Score (Motor Strength)
48Chapter 7: Treatment — Managing and Treating CIDP
106I-RODS (Inflammatory Rasch-Built Overall Disability Scale)
497.1 The Goals and Philosophy of CIDP Treatment
107Overall Neuropathy Limitations Scale (ONLS)
507.2 First-Line Treatments
108Modified Rankin Scale (mRS)
517.2.1 Corticosteroids (Steroids)
109Patient Global Impression of Change (PGIC)
527.2.2 Intravenous Immunoglobulin (IVIG)
110Appendix E: Medication Reference Card
537.2.3 Plasma Exchange (Plasmapheresis)
111Appendix F: Resources and Support Organizations
547.3 Subcutaneous Immunoglobulin (SCIg): Independence and Convenience
112Patient and Family Support
557.3.1 Conventional SCIg (Hizentra, Cuvitru)
113Clinical and Research Information
567.3.2 HyQvia (Facilitated SCIg / fSCIg)
114Disability and Practical Support (United States)
577.4 The 2023 Breakthrough: Efgartigimod Alfa (Vyvgart Hytrulo)
115Mental Health and Wellness
58The Science: How FcRn Inhibition Works

More from Daniel Schwartz

You may also like

The Reason Why
The Reason WhyJohn Long and The Dasilva Theatre Players9m$2 · $0.00
Smarter Not Harder
Smarter Not HarderDave Asprey8h 32m$26 · $0.00
The Lettsomian Lectures on Diseases and Disorders of the Heart and Arteries
The Lettsomian Lectures on Diseases and Disorders of the Heart and ArteriesJ. Mitchell Bruce1h 14m$2 · $0.00
Signals
SignalsDr. Saira Hameed10h 6m$29 · $0.00
Medically Unexplained Symptoms
Medically Unexplained SymptomsRobert W. Baloh13h 7m$23
The Omega Rx Zone
The Omega Rx ZoneBarry Sears2h 30m$18 · $0.00
Fix Your Mycobiome Get Gut Balance Quickly For Digestive Well-being
Fix Your Mycobiome Get Gut Balance Quickly For Digestive Well-beingJideon F Marques10h 44m$12 · $0.00
Clean Gut
Clean GutAlejandro Junger5h 20m$24 · $0.00
Pain
PainScientific American9h 15m$20
The Art of Invigorating and Prolonging Life
The Art of Invigorating and Prolonging LifeWilliam Kitchiner3h 29m$2 · $0.00
The Diet Myth
The Diet MythTim Spector12h 44m$20
The Beautiful Cure
The Beautiful CureDaniel M. Davis8h 24m$20 · $0.00
Goodbye to Inflammation
Goodbye to InflammationSandra Monino5h 46m$24 · $0.00
The Ultimate Diabetes Book
The Ultimate Diabetes BookDr. Ahmet Ergin11h 33m$20
The Sleep Fix
The Sleep FixDiane Macedo8h 16m$26 · $0.00
Change by Design
Change by DesignTim Brown6h 48m$24 · $0.00
On Snake-Poison: Its Action and Its Antidote
On Snake-Poison: Its Action and Its AntidoteA. Mueller2h 46m$1 · $0.00
De Medicina (All 8 Volumes)
De Medicina (All 8 Volumes)Aulus Cornelius Celsus20h 27m$2 · $0.00
Finally Relaxed! Learn Composure, Reduce Stress and Relieve Tension Sustainably With Effective Relaxation Techniques - Incl. The Best Tips for Stress Reduction
Finally Relaxed! Learn Composure, Reduce Stress and Relieve Tension Sustainably With Effective Relaxation Techniques - Incl. The Best Tips for Stress ReductionLuisa Feldkamp1h 26m$12 · $0.00
The Knack of Managing
The Knack of ManagingLewis K. Urquhart, Herbert Watson3h 5m$1 · $0.00